SecProbe.io

CORRESP
1
filename1.htm

        November 20, 2024

        VIA EDGAR

        U.S. Securities and Exchange Commission

        Division of Corporation Finance

        100 F Street, N.E.

        Washington, DC 20549

                  Attention:

                    Tamika N. Sheppard

                   Re:

                  Gyre Therapeutics, Inc.

                  Registration Statement on Form S-3 (File No. 333-283237)

        Ladies and Gentlemen:

        Gyre Therapeutics, Inc. hereby respectfully requests that, pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended, the effectiveness of the above-referenced
          Registration Statement on Form S‑3 be accelerated so that it will become effective on November 22, 2024, at 4:15 p.m., Eastern Time, or as soon as practicable thereafter, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request
          by telephone that such Registration Statement be declared effective at some other time.

        We request that we be notified of such effectiveness by a telephone call to Branden C. Berns of Gibson, Dunn & Crutcher at (415) 393-4631.

              Sincerely,

              GYRE THERAPEUTICS, INC.

              By:

                /s/ Han Ying

              Han Ying, Ph.D.

              Chief Executive Officer

              cc:

              Ruoyu Chen, Gyre Therapeutics, Inc.

              Ryan A. Murr, Gibson, Dunn & Crutcher LLP

              Branden C. Berns, Gibson, Dunn & Crutcher LLP